160 related articles for article (PubMed ID: 11051263)
1. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.
Hull GW; Mccurdy MA; Nasu Y; Bangma CH; Yang G; Shimura S; Lee HM; Wang J; Albani J; Ebara S; Sato T; Timme TL; Thompson TC
Clin Cancer Res; 2000 Oct; 6(10):4101-9. PubMed ID: 11051263
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.
Nasu Y; Bangma CH; Hull GW; Lee HM; Hu J; Wang J; McCurdy MA; Shimura S; Yang G; Timme TL; Thompson TC
Gene Ther; 1999 Mar; 6(3):338-49. PubMed ID: 10435084
[TBL] [Abstract][Full Text] [Related]
3. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer.
Nasu Y; Bangma CH; Hull GW; Yang G; Wang J; Shimura S; McCurdy MA; Ebara S; Lee HM; Timme TL; Thompson TC
Prostate Cancer Prostatic Dis; 2001; 4(1):44-55. PubMed ID: 12497062
[TBL] [Abstract][Full Text] [Related]
4. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
[TBL] [Abstract][Full Text] [Related]
5. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model.
Satoh T; Saika T; Ebara S; Kusaka N; Timme TL; Yang G; Wang J; Mouraviev V; Cao G; Fattah el MA; Thompson TC
Cancer Res; 2003 Nov; 63(22):7853-60. PubMed ID: 14633713
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
7. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of adoptive splenocyte transfer following in situ AdIL-12 gene therapy in a mouse prostate cancer model.
Saika T; Kusaka N; Mouraviev V; Satoh T; Kumon H; Timme TL; Thompson TC
Cancer Gene Ther; 2006 Jan; 13(1):91-8. PubMed ID: 16052232
[TBL] [Abstract][Full Text] [Related]
9. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
10. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
11. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma.
Wen XY; Mandelbaum S; Li ZH; Hitt M; Graham FL; Hawley TS; Hawley RG; Stewart AK
Cancer Gene Ther; 2001 May; 8(5):361-70. PubMed ID: 11477456
[TBL] [Abstract][Full Text] [Related]
12. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
14. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
15. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor immunity against pre-established primary tumor and pulmonary metastasis of rat osteosarcoma.
Tsuji H; Kawaguchi S; Wada T; Nagoya S; Inobe M; Yamashita T; Ishii S; Uede T
Cancer Gene Ther; 2002 Sep; 9(9):747-55. PubMed ID: 12189524
[TBL] [Abstract][Full Text] [Related]
19. Autologous lymphocyte responses to adenovirus-B7-1-transduced human cancer cells.
Dessureault S; Graham FL; Gallinger S
Cancer Gene Ther; 1999; 6(3):195-208. PubMed ID: 10359205
[TBL] [Abstract][Full Text] [Related]
20. B7.1 immunogene therapy effectively activates CD(4+) tumor-infiltrating lymphocytes in the central nervous system in comparison with B7.2 gene therapy.
Ando H; Saio M; Ohe N; Tamakawa N; Yu H; Nakayama T; Yoshimura S; Kaku Y; Iwama T; Shinoda J; Sakai N; Takami T
Int J Oncol; 2002 Apr; 20(4):807-12. PubMed ID: 11894129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
